Overview
Nectar Lifesciences Ltd is a leading global pharmaceutical company specializing in the manufacturing of Cephalosporin APIs and formulations. It holds a strong market position due to its integrated manufacturing ecosystem, allowing it to excel in advanced pharmaceutical production and distribution capabilities.
The company's recent performance highlights a significant increase in PAT by 399.36% YoY in Q3 FY25, driven by operational efficiencies and process improvements.
Nectar is actively expanding its contract development and manufacturing organization (CDMO) business, leveraging its extensive manufacturing capabilities to enhance customer relationships and reduce supply chain risks.
The company is strategically reducing long-term debt to zero by FY26 through efficient cost management, which is expected to enhance profitability and facilitate self-funded growth initiatives.
- Sector
Pharmaceuticals & Biotechnology
- Industry
Pharmaceuticals
- Market Cap
225 Cr
- Volatility
Moderate Risk
- P/E Ratio
-0.8
- Industry P/E
33.7
- PEG Ratio
—
- P/B Ratio
0.4
- 52W High
25.53
- 52W Low
9.20
Financial Ratios
Sales CAGR
- 1Y
- -0.84%
- 3Y
- -0.29%
- 5Y
- -6.28%
- 10Y
- 0.69%
Profit CAGR
- 1Y
- -2373.60%
- 3Y
- —
- 5Y
- —
- 10Y
- —
ROE
- TTM
- -9.85%
- 3Y
- -4.30%
- 5Y
- -3.46%
- 10Y
- 0.57%
ROCE
- TTM
- -8.75%
- 3Y
- 1.57%
- 5Y
- 3.15%
- 10Y
- 8.56%
Actions
AI Mode
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Ask AI
